Skip to content
Homepage
Author:
Celcuity Inc.
Posted Date:
June 3, 2026
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Celcuity Inc.
June 3, 2026
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Celcuity Inc.
June 3, 2026
Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
Celcuity Inc.
June 2, 2026
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
Celcuity Inc.
June 1, 2026
Celcuity To Participate in Upcoming Investor Conferences
Celcuity Inc.
May 28, 2026
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Celcuity Inc.
May 15, 2026
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
Celcuity Inc.
May 14, 2026
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
Celcuity Inc.
May 8, 2026
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
Celcuity Inc.
May 8, 2026
Celcuity’s Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Celcuity Inc.
May 1, 2026
1
2
Next
